Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires 1,500 Shares of Stock

by · The Cerbat Gem

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) CEO Snehal Patel purchased 1,500 shares of the stock in a transaction dated Thursday, September 26th. The stock was purchased at an average price of $14.63 per share, for a total transaction of $21,945.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,536,102 shares in the company, valued at approximately $80,993,172.26. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Snehal Patel also recently made the following trade(s):

  • On Monday, August 5th, Snehal Patel purchased 5,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $13.18 per share, for a total transaction of $72,490.00.
  • On Tuesday, July 23rd, Snehal Patel purchased 1,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $15.89 per share, for a total transaction of $23,835.00.

Greenwich LifeSciences Stock Performance

NASDAQ:GLSI opened at $13.97 on Thursday. The company’s 50-day simple moving average is $14.36 and its 200-day simple moving average is $15.01. The stock has a market capitalization of $179.93 million, a P/E ratio of -19.40 and a beta of 1.61. Greenwich LifeSciences, Inc. has a fifty-two week low of $7.58 and a fifty-two week high of $21.44.

Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter, hitting analysts’ consensus estimates of ($0.20). On average, research analysts forecast that Greenwich LifeSciences, Inc. will post -0.81 EPS for the current year.

Institutional Trading of Greenwich LifeSciences

A number of institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers acquired a new stake in Greenwich LifeSciences in the 2nd quarter worth approximately $117,000. Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences in the 2nd quarter worth approximately $264,000. Finally, Vanguard Group Inc. boosted its stake in Greenwich LifeSciences by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after purchasing an additional 1,420 shares in the last quarter. 4.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised their price target on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a report on Friday, August 23rd.

Read Our Latest Stock Report on GLSI

Greenwich LifeSciences Company Profile

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Further Reading